SYDNEY--()--TranScrip Partners, the rapidly growing, cutting-edge contract organisation are pleased to announce the opening of their new office, TranScrip Partners (Australia) Pty Ltd in Sydney, NSW, Australia. "This provides a tremendous opportunity to bring the breadth and depth of top level expertise and experience of the global team of TranScrip Partners to the highly innovative biotech and pharmaceutical companies here in Australia and Asia Pacific" commented Dr Bernadette Morris-Smith, who heads the Australian office.
“We are excited to be growing a team of like-minded experts in Australia which will enable us to contribute to global programs in both hemispheres as well as in the emerging markets of the Asia Pacific region.”
Dr Morris-Smith added that "Australia is home to many discoveries which have had global impact. Australia offers a cost effective solution to clinical trial recruitment and an efficient and transparent regulatory system”.
Working for more than 50 companies across 4 continents, TranScrip Partners supports biopharmaceutical product development and life cycle management globally. TranScrip Partners challenge the traditional CRO model by offering to clients, on a global basis, top level expertise and previous experience in overcoming the hurdles encountered from translational medicine to successful registration and market access. The launch of the Australian office marks a relevant and important milestone in the expansion of TranScrip Partners.
TranScrip Partners are "strategic thinkers who do, and doers who think strategically" says Founding and Managing Partner, Dr Flic Gabbay. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical monitoring, pharmacovigilance, strategic regulatory affairs and medical writing across a range of therapy areas.
TranScrip Partners comprises full time senior level clinical and regulatory staff and consistently delivers high quality work to meet client needs. The unique character of its organisational model, acting as a flexible “one stop shop”, offers an innovative solution to manage the ever increasing costs of fixed overheads in Pharmaceutical R&D. "We are excited to be growing a team of like-minded experts in Australia which will enable us to contribute to global programs in both hemispheres as well as in the emerging markets of the Asia Pacific region." says Dr Flic Gabbay.